{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:45:51Z","timestamp":1789836351390,"version":"4.0.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Project Program of the State Key Laboratory of Natural Medicines, China Pharmaceutical University","award":["SKLNMZZ2024JS06"],"award-info":[{"award-number":["SKLNMZZ2024JS06"]}]},{"name":"Key Research and Development Project of Guangdong Province","award":["2022B1111070004"],"award-info":[{"award-number":["2022B1111070004"]}]},{"name":"National Key Research and Development Program of China","award":["2018YFA0902000"],"award-info":[{"award-number":["2018YFA0902000"]}]},{"name":"\u201cDouble First-Class\u201d University Project","award":["CPU2022QZ008"],"award-info":[{"award-number":["CPU2022QZ008"]}]},{"name":"the MOST of China","award":["2018YFA0902000, 2019ZX09721-001-04-01"],"award-info":[{"award-number":["2018YFA0902000, 2019ZX09721-001-04-01"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["No. 21778076"],"award-info":[{"award-number":["No. 21778076"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Antimicrob Resist"],"DOI":"10.1038\/s44259-025-00148-6","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T07:11:51Z","timestamp":1756710711000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacokinetic and pharmacodynamic studies of injectable nocathiacin as a novel antibacterial agent"],"prefix":"10.1038","volume":"3","author":[{"given":"Xisheng","family":"Xiong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjian","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuri","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"148_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkf801","volume":"50","author":"D Adam","year":"2002","unstructured":"Adam, D. Global antibiotic resistance in Streptococcus pneumoniae. J. Antimicrob. Chemother. 50, 1\u20135 (2002).","journal-title":"J. Antimicrob. Chemother."},{"key":"148_CR2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/jac\/dkg270","volume":"52","author":"SS Andrade","year":"2003","unstructured":"Andrade, S. S., Jones, R. N., Gales, A. C. & Sader, H. S. Increasing prevalence of antimicrobial resistance among Pseudomonas aeruginosa isolates in Latin American medical centres: 5 year report of the SENTRY Antimicrobial Surveillance Program (1997-2001). J. Antimicrob. Chemother. 52, 140\u2013141 (2003).","journal-title":"J. Antimicrob. Chemother."},{"key":"148_CR3","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1021\/cr0300441","volume":"105","author":"MC Bagley","year":"2005","unstructured":"Bagley, M. C., Dale, J. W., Merritt, E. A. & Xiong, X. Thiopeptide antibiotics. Chem. Rev. 105, 685\u2013714 (2005).","journal-title":"Chem. Rev."},{"key":"148_CR4","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.1093\/cid\/ciu296","volume":"59","author":"DL Stevens","year":"2014","unstructured":"Stevens, D. L. et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 59, e10\u2013e52 (2014).","journal-title":"Clin. Infect. Dis."},{"key":"148_CR5","doi-asserted-by":"publisher","first-page":"78","DOI":"10.4103\/0974-777X.157245","volume":"7","author":"DC Kaur","year":"2015","unstructured":"Kaur, D. C. & Chate, S. S. Study of antibiotic resistance pattern in methicillin resistant Staphylococcus Aureus with special reference to newer antibiotic. J. Global Infect. Dis. 7, 78\u201384 (2015).","journal-title":"J. Global Infect. Dis."},{"key":"148_CR6","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1128\/AAC.01088-08","volume":"53","author":"A Forouzesh","year":"2009","unstructured":"Forouzesh, A., Moise, P. A. & Sakoulas, G. Vancomycin ototoxicity: a reevaluation in an era of increasing doses. Antimicrob. Agents Chemother. 53, 483\u2013486 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"key":"148_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1517\/14740330903413514","volume":"9","author":"ED Hermsen","year":"2010","unstructured":"Hermsen, E. D. et al. Clinical outcomes and nephrotoxicity associated with vancomycin trough concentrations during treatment of deep-seated infections. Expert Opin. Drug Saf. 9, 9\u201314 (2010).","journal-title":"Expert Opin. Drug Saf."},{"key":"148_CR8","first-page":"694","volume":"19","author":"FR Bruniera","year":"2015","unstructured":"Bruniera, F. R. et al. The use of vancomycin with its therapeutic and adverse effects: a review. Eur. Rev. Med. Pharmacol. Sci. 19, 694\u2013700 (2015).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"148_CR9","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1128\/AAC.34.11.2114","volume":"34","author":"WR Outman","year":"1990","unstructured":"Outman, W. R., Nightingale, C. H., Sweeney, K. R. & Quintiliani, R. Teicoplanin pharmacokinetics in healthy volunteers after administration of intravenous loading and maintenance doses. Antimicrob. Agents Chemother. 34, 2114\u20132117 (1990).","journal-title":"Antimicrob. Agents Chemother."},{"key":"148_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1080\/1120009X.2000.11782313","volume":"12","author":"I Harding","year":"2000","unstructured":"Harding, I. & Sorgel, F. Comparative pharmacokinetics of teicoplanin and vancomycin. J. Chemother. 12, 15\u201320 (2000).","journal-title":"J. Chemother."},{"key":"148_CR11","doi-asserted-by":"publisher","first-page":"184","DOI":"10.2165\/00003088-199018030-00002","volume":"18","author":"M Rowland","year":"1990","unstructured":"Rowland, M. Clinical pharmacokinetics of teicoplanin. Clin. Pharmacokinet. 18, 184\u2013209 (1990).","journal-title":"Clin. Pharmacokinet."},{"key":"148_CR12","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.ijantimicag.2010.07.011","volume":"36","author":"M Bassetti","year":"2010","unstructured":"Bassetti, M. et al. High-dose daptomycin in documented Staphylococcus aureus infections. Int. J. Antimicrob. Agents 36, 459\u2013461 (2010).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"148_CR13","doi-asserted-by":"publisher","first-page":"e63","DOI":"10.1086\/652656","volume":"50","author":"BA Miller","year":"2010","unstructured":"Miller, B. A. et al. Acute eosinophilic pneumonia secondary to daptomycin: a report of three cases. Clin. Infect. Dis. 50, e63\u2013e68 (2010).","journal-title":"Clin. Infect. Dis."},{"key":"148_CR14","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1021\/acscentsci.8b00344","volume":"4","author":"M Czuban","year":"2018","unstructured":"Czuban, M. et al. Bio-orthogonal chemistry and reloadable biomaterial enable local activation of antibiotic prodrugs and enhance treatments against Staphylococcus aureus infections. ACS Cent. Sci. 4, 1624\u20131632 (2018).","journal-title":"ACS Cent. Sci."},{"key":"148_CR15","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.jgar.2020.12.009","volume":"24","author":"H Kato","year":"2021","unstructured":"Kato, H. et al. Meta-analysis of vancomycin versus linezolid in pneumonia with proven methicillin-resistant Staphylococcus aureus. J. Glob Antimicrob. Resist. 24, 98\u2013105 (2021).","journal-title":"J. Glob Antimicrob. Resist."},{"key":"148_CR16","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1007\/s10096-017-2934-7","volume":"36","author":"I Gawryszewska","year":"2017","unstructured":"Gawryszewska, I., \u017babicka, D., Hryniewicz, W. & Sadowy, E. Linezolid-resistant enterococci in Polish hospitals: species, clonality and determinants of linezolid resistance. Eur. J. Clin. Microbiol. Infect. Dis. 36, 1279\u20131286 (2017).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"148_CR17","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.2147\/IDR.S181339","volume":"11","author":"M Chen","year":"2018","unstructured":"Chen, M. et al. Epidemiological characteristics and genetic structure of linezolid-resistant Enterococcus faecalis. Infect. Drug Resist. 11, 2397\u20132409 (2018).","journal-title":"Infect. Drug Resist."},{"key":"148_CR18","doi-asserted-by":"crossref","unstructured":"John, J. Jr. The treatment of resistant staphylococcal infections. F1000Res. 9, F1000 Faculty Rev-150 (2020).","DOI":"10.12688\/f1000research.17718.1"},{"key":"148_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.molcel.2008.01.009","volume":"30","author":"JM Harms","year":"2008","unstructured":"Harms, J. M. et al. Translational regulation via L11: molecular switches on the ribosome turned on and off by thiostrepton and micrococcin. Mol Cell. 30, 26\u201338 (2008).","journal-title":"Mol Cell."},{"key":"148_CR20","unstructured":"Bristol-Myers Squibb Company. Nocathiacin antibiotics: US09351791 (Bristol-Myers Squibb Company, 2001)."},{"key":"148_CR21","doi-asserted-by":"publisher","first-page":"8699","DOI":"10.1021\/jo0261698","volume":"67","author":"A Regueiro-Ren","year":"2002","unstructured":"Regueiro-Ren, A. & Ueda, Y. Mild method for cleavage of dehydroalanine units: highly efficient conversion of nocathiacin I to nocathiacin IV. J. Org. Chem. 67, 8699\u20138702 (2002).","journal-title":"J. Org. Chem."},{"key":"148_CR22","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.1016\/j.bmcl.2004.04.102","volume":"14","author":"BN Naidu","year":"2004","unstructured":"Naidu, B. N. et al. Synthesis and antibacterial activity of O-substituted nocathiacin I derivatives. Bioorg. Med. Chem. Lett. 14, 3743\u20133746 (2004).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"148_CR23","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1021\/np040225d","volume":"68","author":"TP Connolly","year":"2005","unstructured":"Connolly, T. P. et al. Chemical conversion of nocathiacin I to nocathiacin II and a lactone analogue of glycothiohexide alpha. J. Nat. Prod. 68, 550\u2013553 (2005).","journal-title":"J. Nat. Prod."},{"key":"148_CR24","doi-asserted-by":"publisher","first-page":"3545","DOI":"10.1016\/j.bmcl.2006.03.079","volume":"16","author":"BN Naidu","year":"2006","unstructured":"Naidu, B. N. et al. Synthesis and antibacterial activity of nocathiacin I analogues. Bioorg. Med. Chem. Lett. 16, 3545\u20133549 (2006).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"148_CR25","doi-asserted-by":"publisher","first-page":"7447","DOI":"10.1021\/jo071115p","volume":"72","author":"L Xu","year":"2007","unstructured":"Xu, L., Farthing, A. K., Shi, Y. J., Meinke, P. T. & Liu, K. Conversion of nocathiacin I to nocathiacin acid by a mild and selective cleavage of dehydroalanine. J. Org. Chem. 72, 7447\u20137450 (2007).","journal-title":"J. Org. Chem."},{"key":"148_CR26","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1016\/j.biortech.2009.12.060","volume":"101","author":"M Wei","year":"2010","unstructured":"Wei, M., Wang, S., Fang, Y. & Chen, Y. Microbial generation of nocathiacin acid from nocathiacin I. Bioresour. Technol. 101, 3617\u20133622 (2010).","journal-title":"Bioresour. Technol."},{"key":"148_CR27","unstructured":"China Pharmaceutical University. Nocathiacin antibiotic drug compositions containing emulsifiers (in Chinese): CN201010548129.8 (China Pharmaceutical University, 2012)."},{"key":"148_CR28","unstructured":"China Pharmaceutical University. Nocathiacin antibiotic drug compositions containing lipid material (in Chinese): CN201010548142.3 (China Pharmaceutical University, 2011)."},{"key":"148_CR29","unstructured":"Nanjing Biotech Pharmaceutical Technology. Drug compositions containing nocathiacin antibiotics (in Chinese): CN201010548134.9 (Nanjing Biotech Pharmaceutical Technology, 2013)."},{"key":"148_CR30","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/ja.2016.165","volume":"70","author":"SB Singh","year":"2017","unstructured":"Singh, S. B. et al. Thiazomycin, nocathiacin and analogs show strong activity against clinical strains of drug-resistant Mycobacterium tuberculosis. J Antibiot. 70, 671\u2013674 (2017).","journal-title":"J Antibiot."},{"key":"148_CR31","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.bmcl.2012.10.065","volume":"23","author":"L Xu","year":"2013","unstructured":"Xu, L. et al. Synthesis and antibacterial activity of novel water-soluble nocathiacin analogs. Bioorg. Med. Chem. Lett. 23, 366\u2013369 (2013).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"148_CR32","unstructured":"Nanjing Biotech Pharmaceutical Technology. A preparation method of lyophilized powder injection of nocathiacin (in Chinese): CN201310044819.3 (Nanjing Biotech Pharmaceutical Technology, 2016)."},{"key":"148_CR33","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1128\/AAC.48.10.3697-3701.2004","volume":"48","author":"MJ Pucci","year":"2004","unstructured":"Pucci, M. J. et al. Antimicrobial evaluation of nocathiacins, a thiazole peptide class of antibiotics. Antimicrob. Agents Chemother. 48, 3697\u20133701 (2004).","journal-title":"Antimicrob. Agents Chemother."},{"key":"148_CR34","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1128\/AAC.01428-12","volume":"57","author":"A Belley","year":"2013","unstructured":"Belley, A. et al. Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic\/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection. Antimicrob. Agents Chemother. 57, 205\u2013211 (2013).","journal-title":"Antimicrob. Agents Chemother."},{"key":"148_CR35","unstructured":"NMPA. Technical guiding principles for clinical pharmacokinetics studies of chemical drugs. https:\/\/www.nmpa.gov.cn\/wwwroot\/gsz05106\/07.pdf (2005)."},{"key":"148_CR36","unstructured":"NMPA. Technical guiding principles for non-clinical pharmacokinetics studies of drugs.http:\/\/www.sfda.gov.cn\/directory\/web\/WS01\/images\/0qnO77fHwdm0stKptPq2r8Gm0afR0L6vLzK9da4tbzUrdTyLmRvYw==.doc (2016)."},{"key":"148_CR37","doi-asserted-by":"publisher","first-page":"e0248579","DOI":"10.1371\/journal.pone.0248579","volume":"16","author":"P Arora","year":"2021","unstructured":"Arora, P., Gudelsky, G. & Desai, P. B. Gender-based differences in brain and plasma pharmacokinetics of letrozole in sprague-dawley rats: application of physiologically-based pharmacokinetic modeling to gain quantitative insights. PloS One. 16, e0248579 (2021). (2021).","journal-title":"PloS One."},{"key":"148_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17225-0","volume":"7","author":"W Chen","year":"2017","unstructured":"Chen, W. et al. Sex-related pharmacokinetic differences and mechanisms of metapristone (RU486 metabolite). Sci Rep. 7, 17190 (2017).","journal-title":"Sci Rep."},{"key":"148_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-83901-7","volume":"15","author":"SR AnandaKumar","year":"2025","unstructured":"AnandaKumar, S. R., Handral, M. & Seekallu, S. Bioavailability study of enantiopure (S)-Equol in CD(SD)IGS rats. Sci Rep. 15, 3141 (2025).","journal-title":"Sci Rep."},{"key":"148_CR40","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.idc.2009.06.013","volume":"23","author":"JM Zuckerman","year":"2009","unstructured":"Zuckerman, J. M., Qamar, F. & Bono, B. R. Macrolides, ketolides, and glycylcyclines: azithromycin, clarithromycin, telithromycin, tigecycline. Infect. Dis. Clin. North. Am. 23, 997\u20131026 (2009).","journal-title":"Infect. Dis. Clin. North. Am."},{"key":"148_CR41","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3390\/biom14010099","volume":"14","author":"J Lee","year":"2024","unstructured":"Lee, J., Beers, J. L., Geffert, R. M. & Jackson, K. D. A review of CYP-mediated drug interactions: mechanisms and in vitro drug-drug interaction assessment. Biomolecules 14, 99 (2024).","journal-title":"Biomolecules"},{"key":"148_CR42","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.copbio.2018.01.026","volume":"54","author":"C Furusawa","year":"2018","unstructured":"Furusawa, C., Horinouchi, T. & Maeda, T. Toward prediction and control of antibiotic-resistance evolution. Curr. Opin. Biotechnol. 54, 45\u201349 (2018).","journal-title":"Curr. Opin. Biotechnol."},{"key":"148_CR43","doi-asserted-by":"publisher","first-page":"eabo7793","DOI":"10.1126\/scitranslmed.abo7793","volume":"14","author":"MA Cook","year":"2022","unstructured":"Cook, M. A. & Wright, G. D. The past, present, and future of antibiotics. Sci. Transl. Med. 14, eabo7793 (2022).","journal-title":"Sci. Transl. Med."},{"key":"148_CR44","doi-asserted-by":"publisher","first-page":"114378","DOI":"10.1016\/j.addr.2022.114378","volume":"187","author":"RYK Chang","year":"2022","unstructured":"Chang, R. Y. K., Nang, S. C., Chan, H. K. & Li, J. Novel antimicrobial agents for combating antibiotic-resistant bacteria. Adv. Drug Deliv Rev. 187, 114378 (2022).","journal-title":"Adv. Drug Deliv Rev."},{"key":"148_CR45","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1021\/acsinfecdis.4c00502","volume":"10","author":"Y Dashti","year":"2024","unstructured":"Dashti, Y. et al. Discovery and biosynthesis of persiathiacins: unusual polyglycosylated thiopeptides active against multidrug resistant tuberculosis. ACS Infect. Dis. 10, 3378\u20133391 (2024).","journal-title":"ACS Infect. Dis."},{"key":"148_CR46","unstructured":"China Pharmaceutical University. A preparation method for polysaccharide nocathiacin (in Chinese): CN202210527595.0 (China Pharmaceutical University, 2022)."},{"key":"148_CR47","first-page":"250","volume":"30","author":"LR Wu","year":"2023","unstructured":"Wu, L. R. et al. Discovery of a novel multi-glycosylated nocathiacin using genome mining (in Chinese). Chin. J. Pharm. Biotechnol. 30, 250\u2013256 (2023).","journal-title":"Chin. J. Pharm. Biotechnol."},{"key":"148_CR48","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1021\/acschembio.1c00952","volume":"17","author":"F Ye","year":"2022","unstructured":"Ye, F. et al. Rational approach to identify RNA targets of natural products enables identification of nocathiacin as an inhibitor of an oncogenic RNA. ACS Chem. Biol. 17, 474\u2013482 (2022).","journal-title":"ACS Chem. Biol."},{"key":"148_CR49","first-page":"23","volume":"4","author":"EL Carmines","year":"1980","unstructured":"Carmines, E. L., Carchman, R. A. & Borzelleca, J. F. A method for the evaluation of dose-effect data utilizing a programmable calculator. J. Environ. Pathol. Toxicol. 4, 23\u201330 (1980).","journal-title":"J. Environ. Pathol. Toxicol."},{"key":"148_CR50","doi-asserted-by":"publisher","first-page":"226","DOI":"10.7164\/antibiotics.56.226","volume":"56","author":"W Li","year":"2003","unstructured":"Li, W. et al. Nocathiacins, new thiazolyl peptide antibiotics from Nocardia sp. I. Taxonomy, fermentation and biological activities. J. Antibiot. 56, 226\u2013231 (2003).","journal-title":"J. Antibiot."},{"key":"148_CR51","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1128\/AAC.06427-11","volume":"56","author":"PR Tessier","year":"2012","unstructured":"Tessier, P. R., Keel, R. A., Hagihara, M., Crandon, J. L. & Nicolau, D. P. Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model. Antimicrob. Agents Chemother. 56, 2342\u20132346 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"148_CR52","doi-asserted-by":"publisher","first-page":"1930","DOI":"10.1016\/j.clinthera.2016.06.015","volume":"38","author":"NJ Onufrak","year":"2016","unstructured":"Onufrak, N. J., Forrest, A. & Gonzalez, D. Pharmacokinetic and pharmacodynamic principles of anti-infective dosing. Clin. Ther. 38, 1930\u20131947 (2016).","journal-title":"Clin. Ther."},{"key":"148_CR53","unstructured":"NMPA. Technical guiding principles for pharmacokinetic\/pharmacodynamic studies of antimicrobial agents. https:\/\/www.nmpa.gov.cn\/directory\/web\/nmpa\/xxgk\/ggtg\/ypggtg\/ypqtggtg\/20170821170301371.html (2017)."},{"key":"148_CR54","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1124\/dmd.30.12.1311","volume":"30","author":"R Yuan","year":"2002","unstructured":"Yuan, R., Madani, S., Wei, X. X., Reynolds, K. & Huang, S. M. Evaluation of cytochrome P450 probe substrates commonly used by the pharmaceutical industry to study in vitro drug interactions. Drug Metab. Dispos. 30, 1311\u20131319 (2002).","journal-title":"Drug Metab. Dispos."},{"key":"148_CR55","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2174\/1568026013395001","volume":"1","author":"Z Yan","year":"2001","unstructured":"Yan, Z. & Caldwell, G. W. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery. Curr. Top. Med. Chem. 1, 403\u2013425 (2001).","journal-title":"Curr. Top. Med. Chem."},{"key":"148_CR56","unstructured":"FDA. In vitro drug interaction studies-cytochrome P450 enzyme- and transporter-mediated drug interactions guidance for industry. https:\/\/www.fda.gov\/drugs\/guidance-compliance-regulatory-information\/guidances-drugs (2020)."}],"container-title":["npj Antimicrobials and Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44259-025-00148-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44259-025-00148-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44259-025-00148-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T11:22:29Z","timestamp":1756898549000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44259-025-00148-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["148"],"URL":"https:\/\/doi.org\/10.1038\/s44259-025-00148-6","relation":{},"ISSN":["2731-8745"],"issn-type":[{"value":"2731-8745","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"16 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"76"}}